SCHEMBL26293222

SCHEMBL26293222

C[C@H](CC(=O)NC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)CCCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 2/20 0.47
PKM P14618 1/20 0.47
HDAC1 Q13547 3/20 0.46
HDAC3 O15379 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC5 Q9UQL6 2/20 0.46
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPK1 P28482 1/20 0.43
ADRA1A P35348 1/20 0.43
HDAC4 P56524 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26293217 0.85 HDAC1 (0.46) HPGDSMN1; SMN2LMNAPKMHDAC1
SCHEMBL26293548 0.80 RECQL (0.51) HPGDHDAC3KMT2AALDH1A1CYP2C19
SCHEMBL26293249 0.80 ALDH1A1 (0.38) HPGDSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL26292977 0.80 NPC1 (0.48) HPGDKMT2AALDH1A1CYP2D6CYP2C9
SCHEMBL12038615 0.79 APAF1 (0.42) HPGDLMNAALDH1A1MAPK1CYP2D6
SCHEMBL26292979 0.79 APAF1 (0.42) HPGDLMNAALDH1A1MAPK1CYP2D6
SCHEMBL30511420 0.79 ACE (0.53)
SCHEMBL26293213 0.79 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AALDH1A1
SCHEMBL16743931 0.78 MAPT (0.41) HPGDLMNAKMT2AALDH1A1MAPK1
SCHEMBL26294391 0.76 MAPT (0.40) HPGDLMNAKMT2AMAPK1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES INC (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME ASNS, SI, NARS1 HPGD 340/4885SMN1; SMN2 1784/4885LMNA 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.